The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
- Registration Number
- NCT02796950
- Lead Sponsor
- University of Aarhus
- Brief Summary
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.
In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 8
- Adult men
- Healthy
- BMI 25-35
- Known DM2
- Receiving hypolipidemic drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Acipimox Acipimox Administration of acipimox 250 mg p.o.
- Primary Outcome Measures
Name Time Method Levels of GLP-1 in plasma 9 months
- Secondary Outcome Measures
Name Time Method Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels 9 months Insulin sensitivity by measuring blood glucose after an OGTT 5 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University Hospital of Aarhus
🇩🇰Aarhus, Denmark